Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)
A Phase I/II Study of Weekly Schedule Of Brentuximab Vedotin Alone and In Combination With 5-Azacytidine In Cluster of Differentiation Antigen (CD30)-Positive Relapsed/Refractory Acute Myeloid Leukemia
Sponsor: M.D. Anderson Cancer Center
Terminated
Slow accrual.
Listed as NCT02096042, this PHASE1/PHASE2 trial focuses on Leukemia and remains terminated or withdrawn. Sponsored by M.D. Anderson Cancer Center, it has been updated 10 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Nov 2023 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Nov 2022 — Nov 2023 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2021 — Nov 2022 [monthly]
Terminated PHASE1_PHASE2
▶ Show 5 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE1_PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
-
Feb 2017 — Oct 2017 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1_PHASE2
First recorded
Apr 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- M.D. Anderson Cancer Center
- Seagen Inc.
For direct contact, visit the study record on ClinicalTrials.gov .